GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

XCell Therapeutics 373110.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

779

-18.34%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩1.95bn

FY2021FY2025

Net income

−₩10.93bn

FY2021FY2025

Free cash flow

−₩10.69bn

FY2021FY2025

Shareholders' equity

₩7.14bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue₩1.95bn₩1.93bn₩1.12bn₩1.02bn₩1.97bn
Gross profit−₩1.95bn₩261.0m−₩258.5m−₩230.6m−₩305.3m
Research and development₩2.58bn₩2.73bn₩2.75bn₩2.60bn₩1.83bn
Operating income−₩10.85bn−₩9.33bn−₩8.86bn−₩8.30bn−₩8.90bn
Net income−₩10.93bn−₩9.54bn−₩9.28bn−₩8.34bn−₩9.04bn
Diluted earnings per share-631.83-874.04-856.91-770.28-818.56

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets₩15.72bn₩16.89bn₩10.47bn₩15.51bn₩23.70bn
Cash and short-term investments—₩8.80bn₩1.36bn₩5.56bn—
Total liabilities₩8.58bn₩7.77bn₩8.08bn₩7.03bn₩7.48bn
Debt₩1.02bn₩5.15bn₩5.84bn₩5.40bn₩870.0m
Shareholders' equity₩7.14bn₩9.12bn₩2.38bn₩8.48bn₩16.22bn
Shares outstanding17m11m11m11m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−₩9.50bn−₩7.00bn−₩6.78bn−₩7.30bn−₩4.61bn
Capital spending−₩1.18bn−₩820.0m−₩233.7m−₩1.32bn−₩1.40bn
Free cash flow−₩10.69bn−₩7.82bn−₩7.02bn−₩8.62bn−₩6.00bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩1.94bn₩1.02bn₩1.06bn₩334.6m₩221.3m₩329.8m₩476.5m₩457.8m
Gross profit−₩549.4m−₩57.7m−₩1.05bn−₩221.4m−₩345.7m₩108.8m−₩174.9m₩110.8m
Operating income−₩2.75bn−₩2.91bn−₩3.26bn−₩2.38bn−₩2.66bn−₩2.56bn−₩2.50bn−₩2.70bn
Net income−₩2.76bn−₩2.93bn−₩3.36bn−₩2.31bn−₩2.70bn−₩2.55bn−₩2.45bn−₩2.69bn
Diluted earnings per share-159.68-169.38-194.54-175.28-205.01-193.49-185.99-246.14
Cash from operations−₩1.74bn−₩3.28bn−₩2.68bn−₩2.86bn−₩1.81bn−₩2.15bn−₩7.00bn−₩5.45bn
Capital spending−₩18.0m−₩13.0m−₩114.0m−₩181.0m−₩37.0m−₩849.0m−₩820.0m−₩301.0m
Free cash flow−₩1.75bn−₩3.29bn−₩2.79bn−₩3.04bn−₩1.85bn−₩2.99bn−₩7.82bn−₩5.75bn
Total assets₩12.63bn₩14.92bn₩15.72bn₩10.56bn₩12.10bn₩14.17bn₩16.89bn₩19.25bn
Cash and short-term investments———————₩11.94bn
Debt₩957.5m₩986.6m₩1.02bn₩1.10bn₩1.07bn₩1.10bn₩1.13bn₩5.24bn
Shareholders' equity₩4.33bn₩6.54bn₩7.14bn₩1.62bn₩4.05bn₩6.47bn₩9.12bn₩11.32bn

Financial ratios

Data as of 24 Sept 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin-100.3%13.5%-23.0%-22.6%-15.5%
Operating margin-556.8%-482.2%-788.3%-813.4%-452.6%
Net margin-560.7%-493.4%-825.7%-817.8%-459.7%
Return on equity-153.1%-104.6%-389.4%-98.3%-55.7%
Return on assets-69.5%-56.5%-88.7%-53.8%-38.1%
Revenue growth0.8%72.1%10.2%-48.1%—
Earnings growth14.5%2.8%11.2%-7.7%—
Current ratio1.81x2.14x0.81x1.39x2.93x
Debt to equity0.14x0.51x2.16x0.57x0.05x
Equity ratio45.4%54.0%22.8%54.7%68.5%
Interest coverage-3161.94x-2118.82x-2837.00x-2871.09x-49.51x
R&D as a share of sales132.2%141.0%244.9%254.5%93.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue22.0%——
Operating income9.4%——
Net income9.4%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-43.6%-36.2%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-2.6-4.7
Price to sales14.822.1

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.